NEW YORK, January 4, 2017 /PRNewswire/
Today, Stock-Callers.com brings focus back on four Generic Drugs equities, namely: Mylan N.V. (NASDAQ: MYL), Allergan PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Catalent Inc. (NYSE: CTLT). According to a press release issued by pharmaceutical manufacturer, PCI Synthesis on December 19th, 2016, there is a potential for significant change for the Generic Drugs industry in 2017, including a possible reduction in FDA red tape, tighter capacity due to the industry's current growth, and a speedier FDA approval process that could reduce its backlog by the end of 2017. Significant uncertainty is also expected this year due to the new political administration in the US. Download the free research reports on these stocks today:http://stock-callers.com/registration
Hertfordshire, the UK-based Mylan N.V.'s shares rose 2.52%, closing Tuesday's trading session at $39.11. The stock recorded a trading volume of 5.03 million shares. Shares of the Company have advanced 8.55% in the last month, 2.38% over the previous three months, and 2.52% on an YTD basis. The stock is trading 5.47% above its 50-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide, have a Relative Strength Index (RSI) of 64.10.
On December 29th, 2016, Mylan announced the US launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg, and 54 mg, a generic version of Janssen's Concerta Tablets. Mylan received final approval from the FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder. See our free and comprehensive research report on MYL at:
On Tuesday, shares in Dublin, Ireland headquartered Allergan PLC recorded a trading volume of 7.93 million shares, which was above their three months average volume of 5.06 million shares. The stock edged 2.94% higher, ending the day at $216.19. The Company's shares have advanced 13.56% in the last month and 2.94% since the start of this year. The stock is trading above its 50-day moving average by 7.90%. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 74.61.
On December 09th, 2016, research firm Credit Suisse reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $301 a share to $274 a share.
On January 03rd, 2017, Allergan announced that it has received approval from the US FDA to market NATRELLE INSPIRA SoftTouch breast implants, offering women undergoing breast reconstruction, augmentation, or revision surgery a new medium firmness gel, or cohesive, implant option. AGN free research report PDF is just a click away at:
Dublin, Ireland headquartered Horizon Pharma PLC's stock finished the day 4.39% higher at $16.89 with a total trading volume of 3.68 million shares. The Company's shares have advanced 4.39% on an YTD basis. The stock is trading below its 200-day moving average by 5.36%. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the US and internationally, have an RSI of 51.16.
On December 16th, 2016, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy' while revising its previous target price from $14 a share to $25 a share.
On December 22nd, 2016, Horizon Pharma announced that it has received a Notice of Allowance from the US Patent and Trademark Office for US patent application number 13/610,580, which covers Horizon's US approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a US patent after administrative processes are completed. The US patent scheduled to issue from this application will expire on September 22nd, 2030. After issuance, Horizon plans to list the US patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Sign up for your complimentary report on HZNP at:
Shares in Somerset, New Jersey headquartered Catalent Inc. ended yesterday's session 0.15% higher at $27.00. The stock recorded a trading volume of 877,273 shares, which was above its three months average volume of 772,560 shares. The Company's shares have advanced 16.73% in the last one month, 4.53% in the previous three months, and 0.15% since the start of this year. The stock is trading 9.00% above its 50-day moving average and 6.33% above its 200-day moving average. Moreover, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 69.79. Register for free on Stock-Callers.com and download the latest research report on CTLT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA